Pharmaceuticals Australia

Australia GLP-1 Receptor Agonists Market Analysis, 2024–2034

Australia GLP-1 Receptor Agonists Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route of Administration, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $617.5 Mn Estimated value
Estimate 2025 $736.7 Mn 1.4% of the global market
Projected 2034 $3.61 Bn 389.5% Adds $2.87 Bn over 9 forecast years
CAGR 2025–2034 19.3% Faster than 82% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Australia is 1.4% of the global market.
  • In APAC, the largest is China at $3.75 Bn.
  • Fastest growing: India at 20.6% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.87 Bn total, 2026–2034

Year-by-year market size, 2024–2034
GLP-1 Receptor Agonists Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $617.5 Mn — —
2025 (base) $736.7 Mn +$119.2 Mn —
2026 (forecast) $878.9 Mn +$142.2 Mn +19.3%
2027 (forecast) $1.05 Bn +$169.6 Mn +42.3%
2028 (forecast) $1.25 Bn +$202.4 Mn +69.8%
2029 (forecast) $1.49 Bn +$241.4 Mn +102.6%
2030 (forecast) $1.78 Bn +$288.0 Mn +141.7%
2031 (forecast) $2.12 Bn +$343.6 Mn +188.3%
2032 (forecast) $2.53 Bn +$409.9 Mn +243.9%
2033 (forecast) $3.02 Bn +$489.0 Mn +310.3%
2034 (forecast) $3.61 Bn +$583.4 Mn +389.5%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $52.46 Bn
  2. North America $27.54 Bn
  3. US $22.68 Bn
  4. Europe $10.02 Bn
  5. APAC $10.15 Bn
  6. Canada $4.26 Bn
  7. China $3.75 Bn
  8. Japan $3.63 Bn
  9. Latin America $2.72 Bn
  10. Middle East $2.30 Bn
  11. Germany $2.03 Bn
  12. Brazil $1.50 Bn
  13. France $1.38 Bn
  14. Italy $1.37 Bn
  15. UK $1.21 Bn
  16. India $1.01 Bn
  17. Saudi Arabia $976.3 Mn
  18. Ecuador $905.6 Mn
  19. Spain $878.1 Mn
  20. Africa $770.4 Mn
  21. Mexico $719.6 Mn
  22. Australia (this report) $736.7 Mn
  23. New Zealand $599.4 Mn
  24. Russia $527.6 Mn
  25. South Africa $346.9 Mn
  26. UAE $244.5 Mn
  27. Egypt $133.9 Mn
  28. Philippines $102.8 Mn
  29. Hong Kong $96.0 Mn
  30. Malaysia $92.6 Mn
  31. Singapore $71.3 Mn
  32. Thailand $59.5 Mn
  33. Kenya $33.8 Mn

The Australia GLP-1 Receptor Agonists Market Analysis Executive Summary

GLP-1 receptor agonists are medicines that mimic a gut hormone to lower blood sugar, slow digestion and reduce appetite. They are used to treat type 2 diabetes and obesity.

Key segments of the GLP-1 Receptor Agonists market include drug (Semaglutide, Tirzepatide and Liraglutide), route of administration (Injectable and Oral) and application (Type 2 Diabetes, Obesity and Cardiovascular Risk Reduction).

Australia GLP-1 Receptor Agonists Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the GLP-1 Receptor Agonists market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the GLP-1 Receptor Agonists market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the GLP-1 Receptor Agonists market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for GLP-1 Receptor Agonists Market in Australia

The GLP-1 Receptor Agonists market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for GLP-1 Receptor Agonists Market in Australia

GLP-1 Receptor Agonists in Australia: rules, payment and health figures

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] Obesity (adults): 30.6% of adults in 2024, the latest WHO figure for Australia.⁠[3]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 11 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for GLP-1 Receptor Agonists. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in GLP-1 Receptor Agonists right now, from free public sources.

Latest research 4,726 papers since 2021 (worldwide)

  1. GLP-1 Receptor Agonist Use and Risk of Pain-Related Medical Encounters Among Patients with Comorbid Type 2 Diabetes and Opioid Use Disorder: A Target Trial Emulation Study. The journal of pain, 2026
  2. Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults - United States, 2025. MMWR. Morbidity and mortality weekly report, 2026
  3. Will sarcopenia preventative pharmacology ensure the long-term success of GLP-1-derived therapies? Expert opinion on pharmacotherapy, 2026
  4. GLP-1 dose escalation and disputed ignition interlock alcohol results: Case report. The Medico-legal journal, 2026
  5. AI-enabled drug repurposing in Alzheimer's disease: from computational nomination to pharmacological proof. Frontiers in pharmacology, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

GLP-1 Receptor Agonists in context

Australia compared

  • Obesity (adults): 30.6% of adults (2024). World: 16.2% of adults (2024). 2nd highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[2]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[3]

Questions, answered with public data

How much research is published on GLP-1 Receptor Agonists?
PubMed lists 4,726 papers added since January 2021 that match this market, worldwide.[4]
What does WHO report for Australia?
Obesity (adults): 30.6 % of adults in 2024, the latest WHO figure.[1]
How many people in Australia are 65 or older?
18.1% of people were 65 or older in 2025.[5]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

[5] World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 13 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about GLP-1 Receptor Agonists in Australia? Our analysts can size it for your plan. Talk to us See the public data Obesity (adults) for every country, free. Open the Public Health Dashboard

From our blog

Weight Management Supplements in the GLP-1 Era2.6 billion adults are overweight. GLP-1 medicines are changing weight care, while most supplements lack… Wound Care: Advanced Dressings for Faster HealingNearly 15% of US Medicare beneficiaries, 8.2 million people, had a wound or wound infection in one year… Snoring and Sleep Apnoea Devices: Sleeping BetterAn estimated 936 million adults have obstructive sleep apnoea, and most are undiagnosed. CPAP machines, oral…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Australia

See all
Same topic, other categories

Related on obesity and diabetes

See the topic